The Medicines Patent Pool signs licence with AbbVie to expand access to key hepatitis C treatment, glecaprevir/pibrentasvir
The licence will enable quality-assured manufacturers to develop and sell generic medicines containing G/P in low- and middle-income countries at affordable prices, enabling access to and treatment scale-up with the most effective pan-genotypic regimens.
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to, and facilitate the development of, life-saving medicines for low- and middle-income countries.
The MPP’s patents and licences database, MedsPaL, is a resource that provides information on the intellectual property status of selected HIV, hepatitis C, tuberculosis and other patented essential medicines in low- and middle-income countries.
Geneva, 3 December 2018: The Medicines Patent Pool (MPP) has confirmed funding awards from two major agencies that will support its mandate expansion into patented essential medicines on the World Health Organization’s (WHO) Essential Medicines List (EML) - and those with strong potential for future inclusion. The Wellcome Trust will grant 105,000 CHF and the Swiss Agency for Development and Cooperation (SDC) will award 248,400.00 CHF.
The MPP was founded in 2010 to increase access to, and facilitate the development of, life-saving medicines for low- and middle-income countries (LMICs) through an innovative approach to voluntary licensing and patent pooling. Initially the foundation worked with HIV, later expanding to hepatitis C and tuberculosis (TB). In 2016, the WHO recommended the expansion of the MPP to “all disease areas, and for all patented essential medicines on the WHO EML to be licensed into the Pool.”
The MPP launched its new five-year strategy in May 2018, which included a feasibility study...
Geneva, 20 November 2018 – The Access to Medicine Index (ATM) has today issued its biennial report giving high-ranking scores in its Patents and Licensing section to those companies that have negotiated licences for antiretrovirals and hepatitis C medicines through the Medicines Patent Pool (MPP). The report acknowledges the role of the MPP as “the central independent driver of access-oriented licensing - and that licences agreed via the MPP include the majority of the access-oriented terms and conditions looked for by the Index.”
The ATM index independently assesses the top 20 pharmaceutical companies on their efforts to improve access to medicines in developing countries, including how companies manage their patents and licensing responsibly and with transparency. The top four places in the Patents and Licensing chapter go to GlaxoSmithKline plc (GSK); Merck & Co., Inc.; Gilead Sciences Inc.; and Bristol-Myers Squibb – all licensing partners of the MPP.
“This is an excellent and important report f...
Important collaboration will ensure affordable hepatitis C treatment options in low- and middle-income countries.
San Francisco, 12 November 2018 – The Medicines Patent Pool (MPP) has today announced a new, royalty-free licence agreement with AbbVie for glecaprevir/pibrentasvir (G/P) – a World Health Organization (WHO)-recommended treatment for people living with chronic hepatitis C (HCV). The licence will enable quality-assured manufacturers to develop and sell generic medicines containing G/P in 99 low- and middle-income countries (LMICs) and territories at affordable prices, enabling access to and treatment scale-up with the most effective pan-genotypic regimens. The agreement was launched at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2018 in San Francisco.
“G/P is a priority therapy for licensing for the MPP, so this agreement with AbbVie is very good news for public health,” said Dr Marie-Paule Kieny, Chair of the MPP Governance Board. “It is a really import...
“The MPP model fits the Swiss approach to improving access because it promotes voluntary, collaborative solutions with the pharmaceutical industry for reducing prices of essential patented products, while ensuring the quality of those medicines, and protect...”
Unable to load twitter timeline, please allow cookie